Real-world treatment patterns and outcomes for patients with extensive-stage small-cell lung cancer treated in US community oncology practices - Summary - MDSpire
Advertisement
Real-world treatment patterns and outcomes for patients with extensive-stage small-cell lung cancer treated in US community oncology practices
To evaluate treatment patterns and clinical outcomes among real-world ES-SCLC patients treated in US community oncology practices, highlighting the significance of these findings for future treatment strategies.
Key Findings:
Among 3,484 eligible patients, 86.6% had de novo and 13.3% had progressive/recurrent ES-SCLC.
The most common 1L treatment was ICI plus platinum-based chemotherapy (73.4%).
58.0% of patients did not receive 2L therapy, with 29.6% receiving non-platinum–based chemotherapy in 2L.
Median rwToT, rwTTNT, and rwOS in 1L were 4.17 months, 6.41 months, and 9.99 months, respectively.
Outcomes worsened with each subsequent line of therapy.
Interpretation:
High utilization of ICI plus chemotherapy in 1L ES-SCLC was observed, consistent with clinical guidelines, but the persistence of poor survival outcomes underscores the need for improved treatment strategies.
Limitations:
Study limited to community oncology settings, which may not represent all treatment practices.
Retrospective design may introduce biases in data collection and patient selection, potentially affecting the reliability of outcomes.
Conclusion:
Despite the uptake of ICI plus chemotherapy, poor survival outcomes highlight substantial unmet needs in ES-SCLC treatment.
